LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

The man had 'tried everything' before Mounjaro gave him a 'life-saving' change, leading to an incredible nine stone weight ...

Women's health doctor Ravina Bhanot, from Zonas Fertility, told LADbible: "Hair loss while taking Mounjaro is a common side effect due to rapid weight loss. It is more likely linked to caloric ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...